Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for Heart Failure Prevention in High BNP Patients (SCREEN-HFI)
NCT00604006Phase 3Completed
- Sponsor
- Monash University
- Start
- Sep 2008
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Spironolactone Arm with Placebo Arm (2 arms). Primary endpoints: Effectiveness of Spironolactone in preventing heart failure at 3 years and Cost effectiveness of Spironolactone prevention at 3 years. Started Sep 2008; status: completed.
02
Drugs
spironolactone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00604006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604006.